Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary StaR® technology and structure-based drug design (SBDD) capabilities are enabling us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, schizophrenia, cancer, migraine, metabolic disease, and other indications. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple pipeline and technology partners including Allergan, AstraZeneca, Kymab, Morphosys, Pfizer and Teva.

Heptares is a wholly owned subsidiary of Sosei Group Corporation.

Latest News

Jan 31, 2017
Heptares Enters a New Research Collaboration under its "ORBIT" Initiative with the University of Cambridge
Dec 8, 2016

Heptares Scientists Solve Structure of CCR9 Chemokine Receptor offering Unique Opportunity to Apply Structure-Based Design across Chemokine Receptor...


Mar 6-8, 2017
Towards Novel Therapies: Emerging Insights from Structural and Molecular Biology
Groningen, the Netherlands
Presenting: Rob Cooke

Mar 12-17, 2017
Gordon Conference on Molecular Pharmacology - GPCRs: From Single Molecules to New Forms of...
Lucca, Italy
Presenting: Fiona Marshall

© 2012-2017 Heptares Therapeutics